Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines of formula
wherein
a is a single or double bond;
R¹ is n-propyl or CH₂R⁵;
R² is H, alkyl, acyl
of
an alkanoic acid, or
R³ is H or alkyl;
R⁴ is H, alkyl; alkenyl cycloalkyl or (CH₂)mC₆H₅ in which m is 0-4 inclusive;
R⁵ is CH=C(R⁶) (R⁷). C≡CH, or cyclopropyl provided that when R⁵ is cyclopropyl, then R², R³ and R⁴ are independently H, and R⁸ is CH₃ or (CH₂)nC₆H₅ in which n is 3-4;
R⁶ and R⁷ independently are H, CH₃ or Cl;
R⁸ is alkyl, alkenyl cycloalkyl or (CH₂)nC₆H₅ is which n is 3-4;
X is O or S;
Y and Z independently are H, OR⁹, NHR⁹, or NR⁹R¹⁰, provided at least one of Y or Z is OR⁹, NHR⁹ , or NR⁹R¹⁰;
R⁹ is H, alkyl or COR¹¹;
R¹⁰ is alkyl or COR¹¹; and
R¹¹ is H or alkyl
have opioid antagonist, and/or appetite-controlling properties. Preferred compounds are kappa receptor selective antagonists.
式中的烷氧基烷基和烷基巯基烷基取代桥
联苯并呋
异喹啉
其中
a 是单键或双键
R¹ 是正丙基或 CH₂R⁵;
R² 是 H、烷基、酰基
的酰基
烷酸的酰基,或
R³ 是 H 或烷基;
R⁴ 是 H、烷基、烯环烷基或 (CH₂)mC₆H₅,其中 m 为 0-4(包括 0-4);
R⁵ 是 CH=C(R⁶) (R⁷)。C≡CH,或环丙基,但当 R⁵ 为环丙基时,R²、R³ 和 R⁴ 独立地为 H,且 R⁸ 为 CH₃ 或 (CH₂)nC₆H₅ 其中 n 为 3-4;
R⁶ 和 R⁷ 独立地为 H、CH₃ 或 Cl;
R⁸ 是烷基、烯基环烷基或 (CH₂)nC₆H₅ ,其中 n 为 3-4;
X 是 O 或 S
Y 和 Z 独立地为 H、OR⁹、NHR⁹ 或 NR⁹R¹⁰,条件是 Y 或 Z 中至少有一个是 OR⁹、NHR⁹ 或 NR⁹R¹⁰;
R𠞙 是 H、烷基或 COR¹¹;
R¹⁰ 是烷基或 COR¹¹;和
R¹¹ 是 H 或烷基
具有阿片类拮抗剂和/或食欲控制特性。首选化合物是卡巴受体选择性拮抗剂。